315 related articles for article (PubMed ID: 36394838)
21. Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials.
Singh R; Lehrer EJ; Wang M; Perlow HK; Zaorsky NG; Trifiletti DM; Bovi J; Navarria P; Scoccianti S; Gondi V; Brown PD; Palmer JD
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):371-384. PubMed ID: 33991621
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
[TBL] [Abstract][Full Text] [Related]
23. Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?
Preusser M; van den Bent MJ
Neuro Oncol; 2023 Apr; 25(4):631-634. PubMed ID: 36562460
[No Abstract] [Full Text] [Related]
24. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
25. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
26. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
[TBL] [Abstract][Full Text] [Related]
27. Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination.
Pasqualetti F; Zanotti S
Br J Cancer; 2023 Oct; 129(6):895-896. PubMed ID: 36792723
[TBL] [Abstract][Full Text] [Related]
28. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Sabel M; Hau P; Kortmann RD; Krex D; Grauer O; Goldbrunner R; Schnell O; Bähr O; Uhl M; Seidel C; Tabatabai G; Kowalski T; Ringel F; Schmidt-Graf F; Suchorska B; Brehmer S; Weyerbrock A; Renovanz M; Bullinger L; Galldiks N; Vajkoczy P; Misch M; Vatter H; Stuplich M; Schäfer N; Kebir S; Weller J; Schaub C; Stummer W; Tonn JC; Simon M; Keil VC; Nelles M; Urbach H; Coenen M; Wick W; Weller M; Fimmers R; Schmid M; Hattingen E; Pietsch T; Coch C; Glas M;
Lancet; 2019 Feb; 393(10172):678-688. PubMed ID: 30782343
[TBL] [Abstract][Full Text] [Related]
29. Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma.
Andrews DW; Judy KD; Scott CB; Garcia S; Harshyne LA; Kenyon L; Talekar K; Flanders A; Atsina KB; Kim L; Martinez N; Shi W; Werner-Wasik M; Liu H; Prosniak M; Curtis M; Kean R; Ye DY; Bongiorno E; Sauma S; Exley MA; Pigott K; Hooper DC
Clin Cancer Res; 2021 Apr; 27(7):1912-1922. PubMed ID: 33500356
[TBL] [Abstract][Full Text] [Related]
30. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
Ballo MT; Conlon P; Lavy-Shahaf G; Kinzel A; Vymazal J; Rulseh AM
J Neurooncol; 2023 Aug; 164(1):1-9. PubMed ID: 37493865
[TBL] [Abstract][Full Text] [Related]
31. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
32. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Omuro A; Brandes AA; Carpentier AF; Idbaih A; Reardon DA; Cloughesy T; Sumrall A; Baehring J; van den Bent M; Bähr O; Lombardi G; Mulholland P; Tabatabai G; Lassen U; Sepulveda JM; Khasraw M; Vauleon E; Muragaki Y; Di Giacomo AM; Butowski N; Roth P; Qian X; Fu AZ; Liu Y; Potter V; Chalamandaris AG; Tatsuoka K; Lim M; Weller M
Neuro Oncol; 2023 Jan; 25(1):123-134. PubMed ID: 35419607
[TBL] [Abstract][Full Text] [Related]
33. DCVax®-L--developed by Northwest Biotherapeutics.
Polyzoidis S; Ashkan K
Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
[TBL] [Abstract][Full Text] [Related]
35. A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma.
Hu JL; Omofoye OA; Rudnick JD; Kim S; Tighiouart M; Phuphanich S; Wang H; Mazer M; Ganaway T; Chu RM; Patil CG; Black KL; Shiao SL; Wang R; Yu JS
Clin Cancer Res; 2022 Feb; 28(4):689-696. PubMed ID: 34862245
[TBL] [Abstract][Full Text] [Related]
36. Tumor Treating Fields (TTFields) therapy vs physicians' choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19).
Zhu JJ; Goldlust SA; Kleinberg LR; Honnorat J; Oberheim Bush NA; Ram Z
Discov Oncol; 2022 Oct; 13(1):105. PubMed ID: 36239858
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
Gridelli C; de Castro Carpeno J; Dingemans AC; Griesinger F; Grossi F; Langer C; Ohe Y; Syrigos K; Thatcher N; Das-Gupta A; Truman M; Donica M; Smoljanovic V; Bennouna J
JAMA Oncol; 2018 Dec; 4(12):e183486. PubMed ID: 30177994
[TBL] [Abstract][Full Text] [Related]
38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
39. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
40. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
